New pharmacotherapies to tackle the unmet needs in bipolar disorder: a focus on acute suicidality
Expert Opin Pharmacother. 2024 Mar 22. doi: 10.1080/14656566.2024.2334425. Online ahead of print.ABSTRACTINTRODUCTION: Suicidal behavior is relatively frequent in patients with bipolar disorder (BD) and constitutes their most frequent cause of death. Suicide rates remain high in patients with BD despite adherence to guidelines recommending lithium as first line, and/or antidepressants, antipsychotics, psychotherapy, psychosocial interventions, and electroconvulsive therapy. Hence the need to identify more effective and rapid anti-suicide interventions.AREAS COVERED: To tackle the unmet needs of pharmacotherapy, we investig...
Source: Expert Opinion on Pharmacotherapy - March 22, 2024 Category: Drugs & Pharmacology Authors: Georgios D Kotzalidis Federica Fiasch è Alessandro Alcibiade Laura Monti Federica Di Segni Marianna Mazza Gabriele Sani Source Type: research
Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review
CONCLUSION: KarXT offers an innovative non-D2 blocking approach, representing a promising treatment avenue for schizophrenia.PMID:38515004 | DOI:10.1080/14656566.2024.2334424 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - March 22, 2024 Category: Drugs & Pharmacology Authors: Alexia Leber Ranuk Ramachandra Felicia Ceban Angela T H Kwan Taeho Greg Rhee Jie Wu Bing Cao Muhammad Youshay Jawad Kayla M Teopiz Roger Ho Gia Han Le Diluk Ramachandra Roger S McIntyre Source Type: research
New pharmacotherapies to tackle the unmet needs in bipolar disorder: a focus on acute suicidality
Expert Opin Pharmacother. 2024 Mar 22. doi: 10.1080/14656566.2024.2334425. Online ahead of print.ABSTRACTINTRODUCTION: Suicidal behavior is relatively frequent in patients with bipolar disorder (BD) and constitutes their most frequent cause of death. Suicide rates remain high in patients with BD despite adherence to guidelines recommending lithium as first line, and/or antidepressants, antipsychotics, psychotherapy, psychosocial interventions, and electroconvulsive therapy. Hence the need to identify more effective and rapid anti-suicide interventions.AREAS COVERED: To tackle the unmet needs of pharmacotherapy, we investig...
Source: Expert Opinion on Pharmacotherapy - March 22, 2024 Category: Drugs & Pharmacology Authors: Georgios D Kotzalidis Federica Fiasch è Alessandro Alcibiade Laura Monti Federica Di Segni Marianna Mazza Gabriele Sani Source Type: research
Current drug strategies for the treatment and control of schistosomiasis
Expert Opin Pharmacother. 2024 Mar 21. doi: 10.1080/14656566.2024.2333372. Online ahead of print.ABSTRACTINTRODUCTION: Schistosomiasis, one of the current Neglected Tropical Diseases (NTDs) affects over 230 million people globally, with nearly 700 million at risk in more than 74 countries. Praziquantel (PZQ) has served as the primary treatment for the past four decades; however, its effectiveness is limited as it solely eliminates adult worms. In regions where infections are frequent, PZQ exhibits only temporary efficacy and has restricted potential to disrupt the prolonged transmission of the disease.AREAS COVERED: A comp...
Source: Expert Opinion on Pharmacotherapy - March 21, 2024 Category: Drugs & Pharmacology Authors: Maria Villamizar-Monsalve Julio L ópez-Abán Bel én Vicente Rafael Pel áez Antonio Muro Source Type: research
Upadacitinib in Crohn's disease
Expert Opin Pharmacother. 2024 Mar 21. doi: 10.1080/14656566.2024.2333964. Online ahead of print.ABSTRACTINTRODUCTION: The small molecule and oral selective and reversible Janus kinase (JAK) inhibitor upadacitinib has been approved for the treatment of moderate to severe active Crohn's disease (CD) in adult patients since April 2023 by EMA/FDA.AREAS COVERED: The approval is based on the two induction studies a maintenance study showing that upadacitinib induction and maintenance therapy was superior to placebo. The approval of upadacitinib in CD expands the therapeutic armamentarium for the management of inflammatory bowel...
Source: Expert Opinion on Pharmacotherapy - March 21, 2024 Category: Drugs & Pharmacology Authors: Axel Dignass Philip Esters Cathrin Flauaus Source Type: research
Current drug strategies for the treatment and control of schistosomiasis
Expert Opin Pharmacother. 2024 Mar 21. doi: 10.1080/14656566.2024.2333372. Online ahead of print.ABSTRACTINTRODUCTION: Schistosomiasis, one of the current Neglected Tropical Diseases (NTDs) affects over 230 million people globally, with nearly 700 million at risk in more than 74 countries. Praziquantel (PZQ) has served as the primary treatment for the past four decades; however, its effectiveness is limited as it solely eliminates adult worms. In regions where infections are frequent, PZQ exhibits only temporary efficacy and has restricted potential to disrupt the prolonged transmission of the disease.AREAS COVERED: A comp...
Source: Expert Opinion on Pharmacotherapy - March 21, 2024 Category: Drugs & Pharmacology Authors: Maria Villamizar-Monsalve Julio L ópez-Abán Bel én Vicente Rafael Pel áez Antonio Muro Source Type: research
Selinexor in multiple myeloma
This article provides a review of selinexor, with a focus on available clinical studies involving MM patients and its safety profile. Clinical trials, such as STORM and BOSTON, have demonstrated its efficacy, particularly in combination regimens, showcasing notable overall response rates (ORR) and prolonged median progression-free survival (mPFS). Selinexor's versatility is evident across various combinations, including carfilzomib-dexamethasone (XKd), lenalidomide-dexamethasone (XRd), and pomalidomide-dexamethasone (XPd), with efficacy observed even in triple-class refractory and high-risk patient populations. However, ch...
Source: Expert Opinion on Pharmacotherapy - March 19, 2024 Category: Drugs & Pharmacology Authors: Enrica Antonia Martino Ernesto Vigna Antonella Bruzzese Caterina Labanca Francesco Mendicino Eugenio Lucia Virginia Olivito Annamaria Zimbo Federica Torricelli Antonino Neri Fortunato Morabito Massimo Gentile Source Type: research
The pharmacological management of asthma in adults: 2023 update
Expert Opin Pharmacother. 2024 Mar 20:1-11. doi: 10.1080/14656566.2024.2332627. Online ahead of print.ABSTRACTINTRODUCTION: The pharmacotherapy of asthma is a dynamic process that changes as our knowledge of the underlying pathophysiology and treatment of this disease continues to evolve. This implies the need for continuous revision of the recommendations of asthma guidelines and strategies.AREAS COVERED: This review summarizes the latest key practical information on the pharmacological management of asthma in adults. We provide the background to the 2023 update of the GINA strategy report, focusing on changes and discuss...
Source: Expert Opinion on Pharmacotherapy - March 18, 2024 Category: Drugs & Pharmacology Authors: Maria Gabriella Matera Barbara Rinaldi Rosa Annibale Vito De Novellis Mario Cazzola Source Type: research
An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis
Expert Opin Pharmacother. 2024 Mar 18. doi: 10.1080/14656566.2024.2331775. Online ahead of print.ABSTRACTINTRODUCTION: Invasive fungal infections, especially candidemia and invasive candidiasis, continue to cause substantial morbidity and mortality. In addition, the emergence of drug-resistant Candida species, notably C. glabrata and C. auris, along with limitations in available treatments, highlights the urgent need for novel, effective antifungal agents.AREAS COVERED: This review discusses the results of in vitro studies evaluating the spectrum and highlights the pharmacokinetic/pharmacodynamic properties. It also includ...
Source: Expert Opinion on Pharmacotherapy - March 18, 2024 Category: Drugs & Pharmacology Authors: Divisha Sharma Jose A Vazquez Source Type: research
The pharmacological management of asthma in adults: 2023 update
Expert Opin Pharmacother. 2024 Mar 18. doi: 10.1080/14656566.2024.2332627. Online ahead of print.ABSTRACTINTRODUCTION: The pharmacotherapy of asthma is a dynamic process that changes as our knowledge of the underlying pathophysiology and treatment of this disease continues to evolve. This implies the need for continuous revision of the recommendations of asthma guidelines and strategies.AREAS COVERED: This review summarizes the latest key practical information on the pharmacological management of asthma in adults. We provide the background to the 2023 update of the GINA strategy report, focusing on changes and discussing a...
Source: Expert Opinion on Pharmacotherapy - March 18, 2024 Category: Drugs & Pharmacology Authors: Maria Gabriella Matera Barbara Rinaldi Rosa Annibale Vito De Novellis Mario Cazzola Source Type: research
An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis
Expert Opin Pharmacother. 2024 Mar 18. doi: 10.1080/14656566.2024.2331775. Online ahead of print.ABSTRACTINTRODUCTION: Invasive fungal infections, especially candidemia and invasive candidiasis, continue to cause substantial morbidity and mortality. In addition, the emergence of drug-resistant Candida species, notably C. glabrata and C. auris, along with limitations in available treatments, highlights the urgent need for novel, effective antifungal agents.AREAS COVERED: This review discusses the results of in vitro studies evaluating the spectrum and highlights the pharmacokinetic/pharmacodynamic properties. It also includ...
Source: Expert Opinion on Pharmacotherapy - March 18, 2024 Category: Drugs & Pharmacology Authors: Divisha Sharma Jose A Vazquez Source Type: research
The pharmacological management of asthma in adults: 2023 update
Expert Opin Pharmacother. 2024 Mar 18. doi: 10.1080/14656566.2024.2332627. Online ahead of print.ABSTRACTINTRODUCTION: The pharmacotherapy of asthma is a dynamic process that changes as our knowledge of the underlying pathophysiology and treatment of this disease continues to evolve. This implies the need for continuous revision of the recommendations of asthma guidelines and strategies.AREAS COVERED: This review summarizes the latest key practical information on the pharmacological management of asthma in adults. We provide the background to the 2023 update of the GINA strategy report, focusing on changes and discussing a...
Source: Expert Opinion on Pharmacotherapy - March 18, 2024 Category: Drugs & Pharmacology Authors: Maria Gabriella Matera Barbara Rinaldi Rosa Annibale Vito De Novellis Mario Cazzola Source Type: research
An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis
Expert Opin Pharmacother. 2024 Mar 18. doi: 10.1080/14656566.2024.2331775. Online ahead of print.ABSTRACTINTRODUCTION: Invasive fungal infections, especially candidemia and invasive candidiasis, continue to cause substantial morbidity and mortality. In addition, the emergence of drug-resistant Candida species, notably C. glabrata and C. auris, along with limitations in available treatments, highlights the urgent need for novel, effective antifungal agents.AREAS COVERED: This review discusses the results of in vitro studies evaluating the spectrum and highlights the pharmacokinetic/pharmacodynamic properties. It also includ...
Source: Expert Opinion on Pharmacotherapy - March 18, 2024 Category: Drugs & Pharmacology Authors: Divisha Sharma Jose A Vazquez Source Type: research
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors
In conclusion, novel therapeutic perspectives are emerging for CML, holding the potential for substantial advancements in disease treatment.PMID:38488824 | DOI:10.1080/14656566.2024.2331778 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - March 15, 2024 Category: Drugs & Pharmacology Authors: Alessandro Costa Emilia Scalzulli Ida Carmosino Claudia Ielo Maria Laura Bisegna Maurizio Martelli Massimo Breccia Source Type: research
